The percutaneous treatment of Patent Foramen Ovale, an effective and safe therapeutic choice

Risultato della ricerca: Articlepeer review


Introduction: The aim of our study is to evaluate the feasibility, safety and efficacy of the percutaneous closure of PFO (abnormal communication between the right and left atrium). Methods: Between July 2009 and October 2012 percutaneous closure was performed in 37 patients. The presence of PFO was diagnosed through the use of ultrasound techniques: transcranial doppler with contrast (cTCD), transthoracic echocardiography(TTE) and transesophageal echocardiography (TEE). Follow-up was composed consisted of a Holter ECG 7 days after the closure with a 24 hour heart rhythm monitoring, to evaluate eventual arrhythmia cases and programmed controls which included a TTE at 1-3 months, TTE+ cTCD at 6-12 months, to evaluate the right positioning of the device and the complete closure of the defect. Results: We obtained 100% of procedural success (correct and stable implantation of the device in a perfect position on the interatrial septum).No complications were recorded during the procedure and no new onset atrial fibrillation was detected in any patients after the PFO closure. The follow up with cTCD and TEE reported a closing rate of 86.7%. No new clinical cerebrovascular events occurred in treated patients until now. Conclusion: Our experience describes the percutaneous PFO procedure as feasible, safe and effective with a high rate of procedural success, with an absence of significant adverse events and a high rate of complete closure. © 2013 Versita Warsaw and Springer-Verlag Berlin Heidelberg.
Lingua originaleEnglish
pagine (da-a)638-643
Numero di pagine6
RivistaCentral European Journal of Medicine
Stato di pubblicazionePublished - 2013

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2700???


Entra nei temi di ricerca di 'The percutaneous treatment of Patent Foramen Ovale, an effective and safe therapeutic choice'. Insieme formano una fingerprint unica.

Cita questo